Improves Motor Function News Today

Data from the RESKUE Phase 1/2 clinical trial continues to demonstrate safety and efficacy post-FBX-101 systemic administration in patients recently receiving hematopoietic stem cell transplantation

ATH434 protects brain cells and improves motor function in Parkinsonian disorder Oral presentation at the American Academy of Neurology News provided by Share this article MELBOURNE, Australia  , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at t...